Every summer since 2010, ten undergraduate students from diverse backgrounds get the opportunity to explore any curiosities they might have about careers in medicine at Memorial Sloan Kettering Cancer Center.
Having had the honor and pleasure to lead an NCI-designated cancer center for several years, I would like to share my thoughts on this small yet unique set of institutes and their value to NCI and the nation.
On Nov. 24, 2003, an article in The Boston Globe told the story of a patient’s remarkable response to gefitinib, a drug that had recently been approved by FDA.
In 2023, Jeffrey S. Weber was named a Fellow of the Academy of Immuno-Oncology, an honor established by the Society for Immunotherapy of Cancer.
Collage art of mammograms of dense breastsIllustrator: Cyrus FineganWhile breast cancer experts are anything but clear on what the words “dense breasts” signify in the clinic, or for that matter, in the English language, FDA appears to be less perplexed.
The FDA Oncologic Drugs Advisory Committee on Sept. 26 voted that PD-L1 inhibitors should not be indicated for patients with PD-L1-negative gastric/gastroesophageal junction adenocarcinoma and esophageal squamous cell carcinoma.
A law group associated with conservative causes and funded by leading conservative donors has sued NIH, HHS, and the National Library of Medicine, demanding that the institutions address PubMed’s inability to display all papers authored by researchers who have published under multiple names.
It is rare that an ABC Movie of the Week endures. Buzz Kulik’s 1971 “Brian’s Song” is a notable exception.
Jose and Irma Russo dedicated their careers to investigating breast cancer, its causes, and potential prevention measures.
A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.
